Conference call to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape will be held on April 11 at 8 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
- Enliven to hold a conference call
- Enliven initiated with a Buy at Mizuho
- Enliven to share initial proof of concept data from ELVN-001 Phase 1 trial
- Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
